302 related articles for article (PubMed ID: 35384000)
1. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
2. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
4. Prothrombin complex concentrate administration timing in warfarin-associated intracranial hemorrhage.
Townsend B; Slechta J; Gilbert BW
Am J Emerg Med; 2024 Feb; 76():136-139. PubMed ID: 38071882
[TBL] [Abstract][Full Text] [Related]
5. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
[TBL] [Abstract][Full Text] [Related]
7. Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage.
Chu C; Tokumaru S; Izumi K; Nakagawa K
Int J Neurosci; 2016; 126(1):62-6. PubMed ID: 25430740
[TBL] [Abstract][Full Text] [Related]
8. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
9. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
[TBL] [Abstract][Full Text] [Related]
10. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
12. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
14. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
Scott R; Kersten B; Basior J; Nadler M
J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
[TBL] [Abstract][Full Text] [Related]
16. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
17. Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience.
Mačiukaitienė J; Bilskienė D; Tamašauskas A; Bunevičius A
Medicina (Kaunas); 2018 Apr; 54(2):. PubMed ID: 30344253
[No Abstract] [Full Text] [Related]
18. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
19. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes after 4F-PCC for warfarin-associated ICH and baseline GCS less than or equal to 8.
Koehl KE; Panos NG; Peksa GD; Slocum GW
Am J Emerg Med; 2022 Sep; 59():59-62. PubMed ID: 35785611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
